

Julian Panes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4775763/publications.pdf>

Version: 2024-02-01

266
papers

25,805
citations

7551

77
h-index

7333

152
g-index

280
all docs

280
docs citations

280
times ranked

22873
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 1118-1125.	9.4	2,284
2	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 376, 1723-1736.	13.9	1,232
3	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. <i>Nature Genetics</i> , 2011, 43, 246-252.	9.4	1,201
4	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 7-27.	0.6	1,050
5	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. <i>Lancet, The</i> , 2016, 388, 1281-1290.	6.3	771
6	Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2012, 367, 616-624.	13.9	716
7	Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review. <i>American Journal of Gastroenterology</i> , 2009, 104, 760-767.	0.2	564
8	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 556-585.	0.6	541
9	Development of the Crohn's disease digestive damage score, the Lönnemann score. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1415-1422.	0.9	496
10	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	0.6	422
11	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2014, 384, 309-318.	6.3	421
12	Magnetic resonance imaging for evaluation of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1759-1768.	0.9	413
13	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. <i>Lancet, The</i> , 2017, 389, 1699-1709.	6.3	364
14	Acute Gastroenteritis Is Followed by an Increased Risk of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2006, 130, 1588-1594.	0.6	351
15	Leukocyte-endothelial cell interactions: Molecular mechanisms and implications in gastrointestinal disease. <i>Gastroenterology</i> , 1998, 114, 1066-1090.	0.6	337
16	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	0.6	331
17	A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. <i>Gut</i> , 2014, 63, 1381-1392.	6.1	317
18	Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2014, 146, 374-382.e1.	0.6	313

#	ARTICLE	IF	CITATIONS
19	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 348-354.e17.	2.4	309
20	VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis. <i>Gastroenterology</i> , 2009, 136, 585-595.e5.	0.6	289
21	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , 2017, 66, 1049-1059.	6.1	274
22	Development of the Lönnemann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2015, 148, 52-63.e3.	0.6	257
23	A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1485-1493.e2.	2.4	256
24	Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. <i>British Journal of Pharmacology</i> , 1999, 126, 537-550.	2.7	226
25	Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. <i>Gut</i> , 2013, 62, 1556-1565.	6.1	221
26	Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease. <i>Gastroenterology</i> , 2013, 145, 766-774.e1.	0.6	221
27	Characterization of Inflammation and Fibrosis in Crohn's Disease Lesions by Magnetic Resonance Imaging. <i>American Journal of Gastroenterology</i> , 2015, 110, 432-440.	0.2	215
28	Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. <i>Gut</i> , 2013, 62, 967-976.	6.1	208
29	European evidence-based Consensus on the management of ulcerative colitis: Special situations. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 63-92.	0.6	206
30	Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECISE 2 Randomized Maintenance Trial Data. <i>American Journal of Gastroenterology</i> , 2010, 105, 1574-1582.	0.2	201
31	Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1541-1550.	2.4	191
32	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 2123-2138.e8.	0.6	189
33	Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. <i>Lancet</i> , The, 2022, 399, 2113-2128.	6.3	187
34	Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 652-664.	8.2	178
35	Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. <i>Gut</i> , 2019, 68, 1115-1126.	6.1	178
36	VCAM-1, but Not ICAM-1 or MAdCAM-1, Immunoblockade Ameliorates DSS-Induced Colitis in Mice. <i>Laboratory Investigation</i> , 2000, 80, 1541-1551.	1.7	172

#	ARTICLE	IF	CITATIONS
37	Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 2139-2149.e14.	0.6	171
38	Crohn's Disease Patients Carrying Nod2/CARD15 Gene Variants Have an Increased and Early Need for First Surgery due to Stricturing Disease and Higher Rate of Surgical Recurrence. <i>Annals of Surgery</i> , 2005, 242, 693-700.	2.1	163
39	Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. <i>Gut</i> , 2017, 66, 2069-2079.	6.1	158
40	Direct evidence of leukocyte adhesion in arterioles by angiotensin II. <i>Blood</i> , 2004, 104, 402-408.	0.6	153
41	Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 840-848.	0.5	146
42	Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 550-561.	0.6	144
43	Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. <i>Journal of Leukocyte Biology</i> , 2004, 76, 537-544.	1.5	141
44	Anrukizumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. <i>Gut</i> , 2015, 64, 894-900.	6.1	137
45	Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn's Disease: A Phase I Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1071-1078.	0.6	135
46	Association Between Response to Etrolizumab and Expression of Integrin β 4 and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 477-487.e9.	0.6	133
47	Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1068-1076.	1.9	132
48	Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study. <i>American Journal of Gastroenterology</i> , 2009, 104, 57-63.	0.2	130
49	The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. <i>Gut</i> , 2011, 60, 1068-1075.	6.1	128
50	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 671-680.	3.7	126
51	Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNF therapy. <i>Gut</i> , 2015, 64, 233-242.	6.1	123
52	Use of Acid-Suppressing Drugs and the Risk of Bacterial Gastroenteritis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1418-1423.	2.4	118
53	Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 927-935.	0.6	117
54	Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 113-118.	1.1	114

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 432-439.e1.	0.6	113
56	Role of leukocyte-endothelial cell adhesion in radiation-induced microvascular dysfunction in rats. <i>Gastroenterology</i> , 1995, 108, 1761-1769.	0.6	109
57	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	6.1	108
58	Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. <i>Journal of Clinical Investigation</i> , 2007, 117, 1951-1960.	3.9	105
59	Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. <i>Lancet, The</i> , 2022, 399, 2031-2046.	6.3	105
60	Anti-VCAM-1 Antibodies did not Protect against Ischemic Damage Either in Rats Or in Mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 421-432.	2.4	104
61	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 377, 496-497.	13.9	102
62	MERTK as negative regulator of human T cell activation. <i>Journal of Leukocyte Biology</i> , 2015, 97, 751-760.	1.5	99
63	Optimising monitoring in the management of Crohn's disease: A physician's perspective. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 653-669.	0.6	96
64	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1158-1169.	0.6	95
65	Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 484-498.	0.6	93
66	Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process. <i>American Journal of Gastroenterology</i> , 2012, 107, 1770-1776.	0.2	93
67	Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 240-251.	0.6	89
68	Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. <i>Gastroenterology</i> , 2022, 162, 1650-1664.e8.	0.6	88
69	A Multicenter, Randomized, Double-Blind Trial of Everolimus Versus Azathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 2284-2292.	0.2	87
70	Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. <i>Respiratory Physiology and Neurobiology</i> , 2007, 155, 93-96.	0.7	85
71	Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2014, 147, 981-989.	0.6	85
72	Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. <i>Gastroenterology</i> , 2016, 150, 96-102.	0.6	83

#	ARTICLE	IF	CITATIONS
73	Comparison of three magnetic resonance enterography indices for grading activity in Crohn's disease. <i>Journal of Gastroenterology</i> , 2017, 52, 585-593.	2.3	83
74	Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 208-212.	0.6	82
75	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 601-606.	0.6	81
76	Health-related quality of life in inflammatory bowel disease patients: The role of psychopathology and personality. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 977-983.	0.9	80
77	Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 717-722.	0.6	80
78	Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 145-156.	0.6	80
79	Integrated microbiota and metabolite profiles link Crohn's disease to sulfur metabolism. <i>Nature Communications</i> , 2020, 11, 4322.	5.8	79
80	Role of P-Selectin and ICAM-1 in Pancreatitis-Induced Lung Inflammation in Rats. <i>Annals of Surgery</i> , 1999, 230, 792.	2.1	79
81	Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest. <i>Gastroenterology</i> , 2017, 152, S1308-S1309.	0.6	77
82	Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 264-273.	0.4	76
83	Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. <i>BMC Gastroenterology</i> , 2015, 15, 14.	0.8	76
84	Commensal-Specific CD4+ Cells From Patients With Crohn's Disease Have a T-Helper 17 Inflammatory Profile. <i>Gastroenterology</i> , 2016, 151, 489-500.e3.	0.6	75
85	Life Events and Inflammatory Bowel Disease Relapse: A Prospective Study of Patients Enrolled in Remission. <i>American Journal of Gastroenterology</i> , 2006, 101, 775-781.	0.2	74
86	Risk of Irritable Bowel Syndrome After an Episode of Bacterial Gastroenteritis in General Practice: Influence of Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 465-469.	2.4	74
87	Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 560-567.	0.4	73
88	Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 752-760.	1.9	73
89	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 464-478.	1.9	73
90	Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G734-G743.	1.6	72

#	ARTICLE	IF	CITATIONS
91	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1594-1602.	0.2	71
92	Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 152, 362-373.e3.	0.6	70
93	Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. <i>BMC Gastroenterology</i> , 2012, 12, 108.	0.8	69
94	Improving quality of care in inflammatory bowel disease: What changes can be made today?. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 919-926.	0.6	65
95	Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 271-280.	1.9	65
96	Risk factors and characteristics of extent progression in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1320-1325.	0.9	63
97	Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. <i>Gut</i> , 2013, 62, 1566-1572.	6.1	61
98	Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract. <i>Current Pharmaceutical Design</i> , 2003, 9, 2253-2266.	0.9	60
99	Crohn's Disease. <i>Drugs</i> , 2007, 67, 2511-2537.	4.9	60
100	Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review. <i>World Journal of Gastroenterology</i> , 2018, 24, 4821-4834.	1.4	59
101	Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1233-1244.e5.	0.6	58
102	Defective IL-10 production in severe phenotypes of Crohn's disease. <i>Journal of Leukocyte Biology</i> , 2009, 85, 896-903.	1.5	56
103	Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1456-1462.	6.1	56
104	Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1161-1168.	0.6	56
105	Comparison of Capsule Endoscopy and Magnetic Resonance Enterography for the Assessment of Small Bowel Lesions in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 775-780.	0.9	56
106	Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. <i>Hepatology</i> , 1994, 20, 336-341.	3.6	52
107	Role of 3.0-T MR Colonography in the Evaluation of Inflammatory Bowel Disease. <i>Radiographics</i> , 2009, 29, 701-719.	1.4	52
108	Accuracy of Advanced Endoscopy and Fecal Calprotectin for Prediction of Relapse in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1187-1193.	0.9	51

#	ARTICLE	IF	CITATIONS
109	Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade [®]] or Conventional Therapy. <i>Journal of Crohn's and Colitis</i> , 2017, 11, j1w221.	0.6	51
110	Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in patients with acute anemia. <i>Transfusion</i> , 1997, 37, 573-576.	0.8	49
111	Steroid-refractory ulcerative colitis: Predictive factors of response to cyclosporine and validation in an independent cohort. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 347-352.	0.9	48
112	Imaging indexes of activity and severity for Crohn's disease: current status and future trends. <i>Abdominal Imaging</i> , 2012, 37, 958-966.	2.0	48
113	Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36 [®] Health Survey. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 600-609.	0.6	48
114	Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 26-31.	0.6	48
115	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 440-449.	0.9	47
116	ICAM-1 upregulation in distant tissues after hepatic ischemia/reperfusion: A clue to the mechanism of multiple organ failure. <i>Journal of Pediatric Surgery</i> , 1998, 33, 350-353.	0.8	46
117	Identification of Risk Loci for Crohn's Disease Phenotypes Using a Genome-Wide Association Study. <i>Gastroenterology</i> , 2015, 148, 794-805.	0.6	46
118	Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. <i>Hepatology</i> , 1994, 19, 55-60.	3.6	45
119	Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem) Tj ETQq1 1 0.784314 rgBT /Over Controlled Trial. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 713-720.	0.7	45
120	Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. <i>Hepatology</i> , 1993, 18, 628-634.	3.6	44
121	Down-Regulation of Endothelial Adhesion Molecules and Leukocyte Adhesion by Treatment with Superoxide Dismutase Is Beneficial in Chronic Immune Experimental Colitis. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 872-882.	0.9	44
122	Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1335-1346.	0.6	44
123	Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 17-27.	3.7	44
124	Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 476-488.	0.6	43
125	A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at <i>10q26</i> . <i>Gut</i> , 2013, 62, 1440-1445.	6.1	42
126	Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 261-268.	0.2	42

#	ARTICLE	IF	CITATIONS
127	Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 950-959.	0.6	42
128	Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 294-306.	3.7	42
129	Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. <i>Hepatology</i> , 1993, 17, 213-218.	3.6	41
130	Time course of anti-inflammatory effect of low-dose radiotherapy: Correlation with TGF- β 1 expression. <i>Radiotherapy and Oncology</i> , 2008, 86, 399-406.	0.3	40
131	Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 389-395.e3.	0.6	40
132	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , 2014, 23, 6927-6934.	1.4	39
133	Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 248-258.	0.6	38
134	Gastric microcirculatory changes of Portal-hypertensive rats can be attenuated by long-term Estrogen-progestagen treatment. <i>Hepatology</i> , 1994, 20, 1261-1270.	3.6	37
135	Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1130-1141.	0.6	37
136	New treatment strategies for ulcerative colitis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 963-973.	1.3	36
137	Role of P-selectin in radiation-induced intestinal inflammatory damage. <i>International Journal of Cancer</i> , 2001, 96, 99-109.	2.3	35
138	Nitric Oxide Supplementation Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice. <i>Laboratory Investigation</i> , 2002, 82, 597-608.	1.7	35
139	Colonic Crohn's disease: value of magnetic resonance colonography for detection and quantification of disease activity. <i>Abdominal Imaging</i> , 2010, 35, 422-427.	2.0	35
140	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 76-87.	0.6	34
141	Determinants of Ethanol and Acetaldehyde Metabolism in Chronic Alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 1993, 17, 48-53.	1.4	33
142	Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation. <i>Journal of Leukocyte Biology</i> , 2004, 75, 214-223.	1.5	33
143	Prevalence of Anal Fistulas in Europe: Systematic Literature Reviews and Population-Based Database Analysis. <i>Advances in Therapy</i> , 2019, 36, 3503-3518.	1.3	33
144	El registro ENEIDA (Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 <i>Hepatology</i> , 2020, 43, 551-558.	0.2	33

#	ARTICLE	IF	CITATIONS
145	Influence of dose-rate on inflammatory damage and adhesion molecule expression after abdominal radiation in the rat. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 1011-1018.	0.4	31
146	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. <i>BioDrugs</i> , 2017, 31, 223-237.	2.2	30
147	Persistent damage on magnetic resonance enterography in patients with Crohn's disease in endoscopic remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1232-1241.	1.9	30
148	H2O2 and PARS mediate lung P-selectin upregulation in acute pancreatitis. <i>Free Radical Biology and Medicine</i> , 2000, 28, 1286-1294.	1.3	29
149	Dissecting Allo-Sensitization After Local Administration of Human Allogeneic Adipose Mesenchymal Stem Cells in Perianal Fistulas of Crohn's Disease Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1244.	2.2	29
150	Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1563-1573.	1.9	29
151	Gram-Negative Enterobacteria Induce Tolerogenic Maturation in Dexamethasone Conditioned Dendritic Cells. <i>PLoS ONE</i> , 2012, 7, e52456.	1.1	29
152	Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 265-276.	1.9	28
153	Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2022-2030.	0.6	28
154	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. <i>Gastroenterology</i> , 2022, 162, 1891-1910.	0.6	28
155	Optimization of technetium-99m-HMPAO leukocyte scintigraphy in evaluation of active inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1828-1835.	1.1	27
156	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2001-2010.	0.6	27
157	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1673-1679.e1.	2.4	26
158	Validation of the Simplified Magnetic Resonance Index of Activity [sMARI] Without Gadolinium-enhanced Sequences for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1074-1081.	0.6	26
159	Protective effect of superoxide dismutase in radiation-induced intestinal inflammation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1159-1166.	0.4	24
160	Development of a Highly Sensitive Ultra-High-Performance Liquid Chromatography Coupled to Electrospray Ionization Tandem Mass Spectrometry Quantitation Method for Fecal Bile Acids and Application on Crohn's Disease Studies. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 5238-5251.	2.4	24
161	Lactobacillus casei prevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G1155-G1162.	1.6	23
162	Imaging of the Colon in Inflammatory Bowel Disease: Ready for Prime Time?. <i>Current Drug Targets</i> , 2012, 13, 1252-1260.	1.0	23

#	ARTICLE	IF	CITATIONS
163	Clinical trials in luminal Crohn's disease: A historical perspective. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1339-1350.	0.6	23
164	Increasing efficiency of MRE for diagnosis of Crohn's disease activity through proper sequence selection: a practical approach for clinical trials. <i>Abdominal Radiology</i> , 2017, 42, 2783-2791.	1.0	23
165	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
166	Probiotic <i>Sonicates</i> Selectively Induce Mucosal Immune Cells Apoptosis through Ceramide Generation via Neutral Sphingomyelinase. <i>PLoS ONE</i> , 2011, 6, e16953.	1.1	23
167	MRI of Crohn's disease: from imaging to pathology. <i>Abdominal Imaging</i> , 2012, 37, 387-396.	2.0	22
168	National differences in ulcerative colitis experience and management among patients from five European countries and Canada: An online survey. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 497-509.	0.6	22
169	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , 2021, 9, 766-772.	1.6	22
170	Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. <i>Hepatology</i> , 1999, 30, 445-453.	3.6	21
171	Are we giving biologics too late? The case for early versus late use. <i>World Journal of Gastroenterology</i> , 2008, 14, 5523.	1.4	21
172	New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. <i>Pharmacogenomics</i> , 2013, 14, 631-640.	0.6	20
173	Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S633-S640.	0.6	20
174	Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 403-412.	0.2	20
175	Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2337-2346.e3.	2.4	20
176	Stem cell treatment for Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 597-605.	1.3	19
177	Evaluation of Responsive Gene Expression as a Sensitive and Specific Biomarker in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 221-229.	0.9	19
178	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 246-255.	0.6	19
179	INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1737-1745.	0.9	19
180	¹²³ Iodine-labelled anti-VCAM-1 antibody scintigraphy in the assessment of experimental colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 31-38.	0.8	18

#	ARTICLE	IF	CITATIONS
181	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 116-131.	0.6	18
182	Central Endoscopy Reading in Inflammatory Bowel Diseases: Table 1.. <i>Journal of Crohn's and Colitis</i> , 2016, 10, S542-S547.	0.6	18
183	Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin) Tj ETQq1 1 0.784314 rgBT /Overlock 816-825.	0.9	18
184	Dissecting Common and Unique Effects of Anti-Î±4Î²7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 441-452.	0.6	17
185	Anemia increases gastric blood flow in noncirrhotic and cirrhotic patients. <i>Gastrointestinal Endoscopy</i> , 1995, 42, 403-407.	0.5	16
186	Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1310-1315.	0.6	16
187	Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICAâ€UC study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1818-1824.	1.4	16
188	Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1852-1863.	0.6	16
189	Neonatal capsaicin treatment does not prevent splanchnic vasodilatation in portal-hypertensive rats. <i>Hepatology</i> , 1994, 20, 1609-1614.	3.6	15
190	Mechanisms underlying the beneficial effects of stem cell therapies for inflammatory bowel diseases. <i>Gut</i> , 2009, 58, 898-900.	6.1	15
191	Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Responseâ€An Observational Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2051-2059.	1.1	15
192	Nanoencapsulated budesonide in self-stratified polyurethane-polyurea nanoparticles is highly effective in inducing human tolerogenic dendritic cells. <i>International Journal of Pharmaceutics</i> , 2016, 511, 785-793.	2.6	14
193	Controlling leukocyte trafficking in IBD. <i>Pharmacological Research</i> , 2020, 159, 105050.	3.1	14
194	Time-course changes in gastric mucosal blood perfusion following portal vein constriction in rats. <i>Journal of Hepatology</i> , 1995, 23, 193-198.	1.8	13
195	Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 958-967.	0.6	13
196	Differences in Peripheral and Tissue Immune Cell Populations Following Haematopoietic Stem Cell Transplantation in Crohnâ€™s Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 634-647.	0.6	13
197	Fructose-1,6-biphosphate and nucleoside pool modifications prevent neutrophil accumulation in the reperfused intestine. <i>Journal of Leukocyte Biology</i> , 2003, 73, 74-81.	1.5	12
198	Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohnâ€™s Disease Intestinal Mucosa: Analysis From the CELEST Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1999-2009.	0.9	12

#	ARTICLE	IF	CITATIONS
199	Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: <sc>ERELATE</sc> Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 463-476.	1.9	12
200	Brain Endothelial Adhesion Molecule Expression in Experimental Colitis. <i>Microcirculation</i> , 2001, 8, 105-114.	1.0	11
201	Efficacy of an inhibitor of adhesion molecule expression (GI270384X) in the treatment of experimental colitis. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G739-G748.	1.6	11
202	Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn's disease. <i>Immunotherapy</i> , 2018, 10, 1203-1217.	1.0	11
203	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 234-245.	0.9	11
204	Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity. <i>European Radiology</i> , 2022, 32, 3334-3345.	2.3	11
205	New MRI modalities for assessment of inflammatory bowel disease. <i>Gut</i> , 2010, 59, 1308-1309.	6.1	10
206	Mesenchymal stem cell therapy of Crohn's disease: are the far-away hills getting closer?. <i>Gut</i> , 2011, 60, 742-744.	6.1	10
207	Anti-TNF antibody therapy in Crohn's disease: the risk of a switch. <i>Gut</i> , 2012, 61, 169-170.	6.1	10
208	Safety and Activity of Dersalazine Sodium in Patients with Mild-to-moderate Active Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2004-2012.	0.9	10
209	Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e126.	1.3	10
210	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 687-694.	0.6	10
211	14 POST-HOC ANALYSIS OF TOFACITINIB CROHN'S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION. <i>Gastroenterology</i> , 2018, 154, S81.	0.6	10
212	Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1148-1157.	0.6	10
213	Magnetic resonance enterography in Crohn's disease: optimal use in clinical practice and clinical trials.. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 66-73.	0.6	9
214	Is the Objective of Treatment for Crohn's Disease Mucosal or Transmural Healing?. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1037-1039.	2.4	9
215	Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 931-946.	1.9	9
216	Psychometric properties of the original Inflammatory Bowel Disease Questionnaire, a Spanish version. <i>Gastroenterología Y Hepatología</i> , 2007, 30, 212-218.	0.2	7

#	ARTICLE	IF	CITATIONS
217	Adalimumab in Ulcerative Colitis: Can Pharmacodynamics Be Improved Based on Pharmacokinetics?. <i>Gastroenterology</i> , 2012, 142, 176-178.	0.6	7
218	Pancreatitis-Associated Protein Does Not Predict Disease Relapse in Inflammatory Bowel Disease Patients. <i>PLoS ONE</i> , 2014, 9, e84957.	1.1	7
219	Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 85-96.	0.9	7
220	P-selectin mediates leukocyte rolling in concanavalin-A-induced hepatitis. <i>Liver International</i> , 2005, 25, 1053-1060.	1.9	6
221	Long-lasting Remission Induced by Syngeneic Haematopoietic Stem Cell Transplantation in a Patient with Refractory Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1122-1124.	0.6	6
222	Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 983-993.	0.9	6
223	Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 1764-1774.	1.4	6
224	Effects of chronic normovolemic anemia on gastric microcirculation and ethanol-induced gastric damage in rats. <i>Digestive Diseases and Sciences</i> , 1994, 39, 751-757.	1.1	5
225	Cell therapies for inflammatory bowel diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 321-324.	1.4	5
226	Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 5-15.	1.4	5
227	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987420.	1.4	5
228	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	0.9	5
229	Telomerase mRNA expression and immunohistochemical detection as a biomarker of malignant transformation in patients with inflammatory bowel disease. <i>Gastroenterology & Hepatology</i> , 2010, 33, 288-296.	0.2	4
230	Rituximab in Active Ulcerative Colitis. <i>Gastroenterology</i> , 2012, 142, 174-176.	0.6	4
231	Regulatory T cells for treatment of Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 315-316.	8.2	4
232	JAK Inhibitors: Back to Small Molecules for the Treatment of IBD. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S711-S712.	0.6	4
233	Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 444-451.	0.6	4
234	Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. <i>Hepatology</i> , 1993, 18, 628-634.	3.6	4

#	ARTICLE	IF	CITATIONS
235	Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. <i>Hepatology</i> , 1994, 20, 336-341.	3.6	4
236	Can we Monitor a Patient with Inflammatory Bowel Disease and Adapt Treatment without Endoscopy?. <i>Current Drug Targets</i> , 2018, 19, 777-781.	1.0	4
237	Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642210796.	1.5	4
238	Adhesion molecules in inflammatory bowel disease. <i>Pathophysiology</i> , 1999, 5, 271-282.	1.0	3
239	Confocal Endomicroscopy in Celiac Disease. <i>Gastroenterology</i> , 2011, 140, 1097-1099.	0.6	3
240	The Crohn's Disease's Disease's Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, e121-e122.	2.4	3
241	Defects in Autophagy Induce Alterations in the Secretory Pathway and Proinflammatory Signaling of Paneth Cells. <i>Gastroenterology</i> , 2009, 137, 1527-1529.	0.6	2
242	New Imaging Standards for Evaluation of Inflammatory Bowel Disease?. <i>Gastroenterology</i> , 2012, 143, 859-862.	0.6	2
243	Small Bowel Imaging: an Update. <i>Current Gastroenterology Reports</i> , 2016, 18, 39.	1.1	2
244	Tu1717 - Tofacitinib for the Treatment of Ulcerative Colitis: Up to 5.4 Years of Safety Data from Global Clinical Trials. <i>Gastroenterology</i> , 2019, 156, S-1097.	0.6	2
245	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 997-998.	1.9	2
246	Integrin Inhibitors in Inflammatory Bowel Disease: From Therapeutic Antibodies to Small-Molecule Drugs. <i>Gastroenterology</i> , 2021, 161, 1791-1793.	0.6	2
247	The classics in perspective. <i>Gut</i> , 2007, 56, 1184-1186.	6.1	1
248	Corrigendum to "European evidence-based consensus on the management of ulcerative colitis: Special situations" [J Crohn's & Colitis 2 (2008) 63-92]. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 191.	0.6	1
249	Response to Chao and Mulani. <i>American Journal of Gastroenterology</i> , 2009, 104, 2354-2355.	0.2	1
250	The 2-Phase Model of Crohn's Disease: From Immune Defect to Hyperresponse. <i>Gastroenterology</i> , 2010, 138, 1204-1206.	0.6	1
251	Optimizing Care of Hereditary Hemorrhagic Telangiectasia. <i>Gastroenterology</i> , 2010, 138, 2014-2016.	0.6	1
252	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis - two cases in real world clinical practice. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1209-1210.	1.9	1

#	ARTICLE	IF	CITATIONS
253	Intestinal Ischemia. , 0, , 858-877.		1
254	Intestinal Ischemia. , 0, , 2811-2830.		0
255	Toward a Safer Use of Thiopurines in Inflammatory Bowel Disease. Gastroenterology, 2010, 138, 1618-1620.	0.6	0
256	Is Lack of "Education" a Mechanism Driving Loss of Tolerance in Crohn's Disease?. Gastroenterology, 2010, 139, 1056-1058.	0.6	0
257	Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis. Current Drug Targets, 2011, 12, 1467-1477.	1.0	0
258	Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases. International Journal of Colorectal Disease, 2013, 28, 1281-1286.	1.0	0
259	Preface. Digestive Diseases, 2013, 31, 185-185.	0.8	0
260	Corrigendum to "Optimising monitoring in the management of Crohn's disease: A physician perspective" [Journal of Crohn's and Colitis volume 7 (2013) 653-669]. Journal of Crohn's and Colitis, 2014, 8, 441.	0.6	0
261	Reply to letter on published paper: Improving quality of care in inflammatory bowel disease: What changes can be made today?. Journal of Crohn's and Colitis, 2014, 8, 1568.	0.6	0
262	Reply. Gastroenterology, 2014, 146, 869-870.	0.6	0
263	MRI scoring indices for evaluation of disease activity and severity in Crohn's disease. The Cochrane Library, 0, , .	1.5	0
264	Response to Gracie and Ford. American Journal of Gastroenterology, 2016, 111, 901-902.	0.2	0
265	Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab. Inflammatory Bowel Diseases, 2021, 27, 1963-1967.	0.9	0
266	Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease" authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 207-208.	1.9	0